摘要
目的:研究尿激酶型纤溶酶原激活剂(urokinasetypeplasminogenactivator,uPA)和纤溶酶原激活剂抑制剂1(plasminogenactivatorinhibitor1,PAI1)在喉癌组织中的表达及其临床意义。方法:应用SABC法检测51例声门上型喉癌患者中的uPA与PAI1的表达,结合临床随访,分析其与临床病理指标的关系及预后的作用。结果:uPA和PAI1的染色阳性率分别为64.7%(33/51)和70.6%(36/51)。uPA和PAI1的表达均与临床分期和颈淋巴结状况相关,与肿瘤大小、T分期和病理学分级无关。单因素分析显示,uPA和PAI1的表达与颈淋巴结转移有相似预后作用;多因素分析显示,uPA和颈淋巴结转移是影响患者预后的独立因子。结论:uPA和PAI1的表达与喉癌的临床分期和颈淋巴结转移有关,uPA阳性表达者可能预后较差。
OBJECTIVE:To study the expression and clinical significance of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in laryngeal squamous cell carcinomas (LSCC). METHODS: Applying SABC immunohistochemical technique, the expressions of uPA and PAI-1 were studied in 51 patients with LSCC. Combined with clinical follow-up, relevance of this expression and conventional clinical pathological factors or prognosis was analyzed.RESULTS: The rates of the positive expression of uPA and PAI-1 were 64.7%(33/51)and 70.6% (36/51), respectively. There was a significant correlation between uPA expression and TNM stage or cervical lymph node status, either between PAI-1 expression and TNM stage or cervical lymph node status. Neither tumor size, T-category, nor grade was significantly related with the level of uPA or PAI-1 expression. Univariate analysis showed that uPA and PAI-1 as prognostic factors were of similar magnitude to cervical lymph node status. In the multivariate analysis, uPA and cervical lymph node status were found to be independent factors related with prognosis. CONCLUSIONS: The expressions of uPA and PAI-1 are positively related with the stage of progression and cervical lymph node metastasis of LSCC, and they may play an important role in LSCC invasion and metastasis. The expression of uPA may indicate to poor prognosis.
出处
《肿瘤防治杂志》
2005年第11期829-832,共4页
China Journal of Cancer Prevention and Treatment
关键词
喉肿瘤
病理学
尿激酶
生物合成
纤溶酶原激活荆抑制剂
生物合成
laryngeal neoplasms/pathology
urokinase/biosynthesis
plasminogen activator inhibitor-1/biosythesis
prognosis
